The trademark ZEPLIFY was filed by Eli Lilly and Company, a U.S. corporation (the "Applicant"). The application was published for oppositions on April 25, 2021, and received one opposition filed on May 26, 2021 by CROSSJECT on Likelihood of confusion. the opponent was represented by CABINET GERMAIN & MAUREAU and proceedings were handled in English, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued May 26, 2021
The application was filed in English, and English was also language of all opposition proceedings (German was selected as the second language).
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and diagnosis of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, diagnosis and prevention of fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, diagnosis and prevention of migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases
Diagnostic agents, preparations and substances for medical purposes
Diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use
Radiopharmaceutical diagnostic preparations for medical use
Radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases